US Declines to Force Lower Price on Cancer Drug Xtandi
WASHINGTON (Reuters) - The U.S. government will not force Pfizer Inc and Astellas Pharma Inc to lower the price of their prostate cancer drug Xtandi using its emergency "march-in" authority, the National Institutes of Health (NIH) said on Tuesday.March-in rights, which have never been used before, allow the government to grant additional licenses to third parties for products developed using federal funds if the original patent holder does not make them available to the public on reasonable terms.Xtandi's wholesale cost is between $160,000-$180,000 per patient a year.Patient group the Union for Affordable Cancer Treatment first filed a petition calling on the NIH to use its authority to lower the drug's price in March 2016.The NIH said in a letter made public on Tuesday that its analyse...